title: Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up.
abstract: OBJECTIVE
  In this prospective observational study, we investigated the efficacy of Stoller afferent nerve stimulation (SANS) in subjects with overactive bladder who failed anticholinergic treatment.
  
  
  METHODS
  Thirty-five subjects with overactive bladder who failed therapy with oxybutynin participated in this study. Treatment (n = 35) was given once a week for 30 minutes for overall 10 weeks. In treatment, SANS device (Urosurge) was used. Subjects were assessed with 3-day voiding diary, SEAPI quality of life questionnaires and cystometry before therapy after completion of therapy and at one-year follow-up.
  
  
  RESULTS
  In 54% (n = 19) of subjects complete recovery was obtained after treatment. Urgency and SEAPI were reduced significantly whereas urine volume increased significantly (p < 0.01). Complete recovery was maintained in eight of the 19 subjects at one year.
  
  
  CONCLUSIONS
  SANS treatment has a short-term positive effect in patients with resistant overactive bladder. However, it was also established that efficacy was maintained at 1 year in only 23% of subjects.
authors.affiliation: 2nd Urology Clinic, Ministry of Health Ankara Training and Teaching Hospital, Republic of Turkey. drbnuhoglu@hotmail.com
authors.forename: Bariş
authors.initials: B
authors.lastname: Nuhoğlu
authors.forename: Vecihi
authors.initials: V
authors.lastname: Fidan
authors.forename: Ali
authors.initials: A
authors.lastname: Ayyildiz
authors.forename: Erim
authors.initials: E
authors.lastname: Ersoy
authors.forename: Cankon
authors.initials: C
authors.lastname: Germiyanoğlu
mesh_terms: D000328:Adult; D000842:Ankle / Q000294:innervation; D004599:Electric Stimulation Therapy / Q000295:instrumentation / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use; D008365:Manometry; D008499:Medical Records; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D009119:Muscle Contraction / Q000502:physiology; D009475:Neurons, Afferent / Q000502:physiology; D011446:Prospective Studies; D011788:Quality of Life; D020127:Recovery of Function / Q000502:physiology; D017211:Treatment Failure; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000503:physiopathology; D014549:Urinary Incontinence / Q000628:therapy*; D014563:Urodynamics / Q000502:physiology
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin